Ixekizumab Results in Persistent Clinical Improvement in Moderateto-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Ixekizumab was efficacious in treating moderate-tosevere genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks. Patients were randomized to 80 mg ixekizumab every 2 weeks or to placebo through Week 12, then received 80 mg open-label ixekizum...

Descripción completa

Detalles Bibliográficos
Autores principales: GUENTHER, Lyn, BLEAKMAN, Alison POTTS, WEISMAN, Jamie, POULIN, Yves, SPELMAN, Lynda, BURGE, Russel, ERICKSON, Janelle, TODD, Kristin, BERTRAM, Clinton C., RYAN, Caitriona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2020
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128873/
https://www.ncbi.nlm.nih.gov/pubmed/31620802
http://dx.doi.org/10.2340/00015555-3353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128873/
https://www.ncbi.nlm.nih.gov/pubmed/31620802
http://dx.doi.org/10.2340/00015555-3353

Ejemplares similares